CymitQuimica ha oltre 25 partner, tra i quali spicca il fornitore TargetMol

PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.

<p>HL389-NHC2-PEG3-C2NH is capable of inhibiting the proliferation of cancer cells MDA-MB-231 and MCF-7, with IC50 values of 11.39 μM and 9.66 μM, respectively. It serves as a conjugate of an E3 ligase ligand and linker, employed in the synthesis of the PROTAC degrader HL435.</p>

<p>5'-Amino-5'-deoxyadenosine (NH2dAdo) is an adenosine kinase inhibitor targeting malignant tumors of the inert lymphatic system with antitumor and anticancer</p>

<p>ROR1-IN-1 (Compound 19h) is an inhibitor of receptor tyrosine kinase-like orphan receptor 1 (ROR1) with a Ki of 0.10 μM. It inhibits the proliferation of cancer cell lines H1975, A549, and MDA-MB-231, with IC50 values of 0.36 μM, 1.37 μM, and 0.47 μM, respectively. In mice, ROR1-IN-1 demonstrates antitumor efficacy and exhibits favorable pharmacokinetic properties in a rat model.</p>

EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.

RGB097 is an efficacious inhibitor of D-dopachrome tautomerase (D-DT), with an IC50 value of 0.5 µM. It holds potential for applications in cancer research.

Anisodine hydrobromide is an inhibitor of adenosine kinase.

<p>COOH-C3-COGN-C7-COOH is a PEG-type PROTAC linker utilized for synthesizing PROTAC Degrader ARM165.</p>

EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research.

Maleimide-Val-Ala-PAB-SNS032 is a conjugated compound used as an ADC toxin and linker. SNS032 acts as a CDK inhibitor, reducing cancer cell viability and arresting the cell cycle at the G1/S phase. Maleimide-Val-Ala-PAB functions as a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 is utilized in the synthesis of ADC molecules.

<p>Diethylene glycol (Diethylenglykol) is a nephrotoxic and neurotoxic compound that can cause acute kidney injury (AKI) when ingested in large amounts.</p>

<p>Antibacterialagent 218 (compound d28) is an orally active inhibitor of sterol 24-C-methyltransferase with an IC50 value of 0.273 μM. It also displays antifungal activity against Candida albicans SC5314, with an IC50 of 0.25 μg/mL.</p>

SDTWS01 is an innovative 68Ga-labeled prostate-specific membrane antigen (PSMA) targeting tracer. It demonstrates high affinity for PSMA with an inhibitory constant (Ki) at the nanomolar level (less than 10 nM). SDTWS01 exhibits significant tumor uptake and enhanced PET imaging effects, making it suitable for diagnostic research in prostate cancer.

FH1 (NSC-12407) (BRD-K4477), a small molecule, enhances the functions of hepatocytes and promotes differentiation hepatocytes derived by iPS.

Antazoline phosphate: H1 histamine receptor antagonist with anticholinergic effects, eases allergies.

CDK7ligand 1 serves as an active control ligand for CDK7ligand 2. CDK7ligand 2 is a ligand for CDK7 and can be used in the synthesis of PROTACs.

Antimalarial agent 41 (Compound 17) exhibits antimalarial activity by inhibiting the malaria parasite Plasmodium falciparum, with IC50 values of 40 nM for NF54 strain and 76 nM for K1 strain. This compound acts as an inhibitor of P. falciparum phosphatidylinositol-4-kinase β (PfPI4K) and hERG channels, with IC50 values of 53 nM and 3 μM, respectively. Additionally, Antimalarial agent 41 shows cytotoxicity against CHO cells, with an IC50 of 34 μM. It can improve malaria infections and demonstrates favorable pharmacokinetic properties in mouse models.

Anti-inflammatory agent 88 (compound 6) is a carbazole derivative found in marine Streptomyces with anti-inflammatory properties. It exerts its effects by inhibiting pro-inflammatory factors and enhancing the expression of anti-inflammatory factors within the Myd88/Nf-κB pathway. This compound holds potential for the development of anti-inflammatory drugs.

EGFR/HER2-IN-15 is a dihydropyrimidine and an effective inhibitor of EGFR/HER2. It significantly suppresses EGFRwt activity with an IC50 of 37.21 nM and exhibits anticancer properties.

Deacyl acebutolol is the major metabolite of Acebutolol.